ACIP Recommendations: Zoster (Shingles) Vaccine

Published in Morbidity and Mortality Weekly Report (MMWR)

The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the CDC regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the CDC Director and, if adopted, are published as official CDC/HHS recommendations in the Morbidity and Mortality Weekly Report (MMWR).

CURRENT Zoster vaccine recommendations

• MMWR. January 21, 2022, Vol 71(3):80–84
  Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
  Print version
• MMWR January 26, 2018, Vol 67(3);103–108
  Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines
  Print version
• MMWR June 6, 2008, Vol 57(05);1-30
  Prevention of Herpes Zoster
  Print version

See also Varicella and MMRV recommendations.

ARCHIVED historical Zoster immunization publications

For your convenience, these archived publications can be used for historical and research purposes.

• MMWR, August 22, 2014, Vol 63(33);729-731
  Update on Recommendations for Use of Herpes Zoster Vaccine
  Print version
• MMWR, November 11, 2011, Vol 60(44);1528-1528
  Update on Herpes Zoster Vaccine: Licensure for Persons Aged 50 Through 59 Years
  Print version

Note: A shingles vaccine called zoster vaccine live (Zostavax) is no longer available for use in the United States, as of November 18, 2020.